MDACC Study No:2010-0113 ( NCT No: NCT01266603)
Title:A Phase II Trial of High Dose Interleukin-2 (HDIL-2) with Recombinant MAGE-A3 Protein Combined with Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients with Unresectable or Metastatic Melanoma
Principal Investigator:Wen-Jen Hwu
Treatment Agent:HDIL-2; recMAGE-A3 + AS15
Study Status:Closed
Study Description:The goal of this pre-screening part of this clinical research study is to
collect a blood and a tumor tissue sample from patients with unresectable or
metastatic melanoma.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:HDIL-2
recMAGE-A3 + AS15
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline Biologicals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults